| Primary |
| Hypertension |
33.7% |
| Product Used For Unknown Indication |
11.1% |
| Cardiac Failure Congestive |
9.4% |
| Cardiac Failure |
9.3% |
| Ill-defined Disorder |
4.4% |
| Cardiac Failure Chronic |
4.3% |
| Coronary Artery Disease |
3.3% |
| Type 2 Diabetes Mellitus |
3.2% |
| Diuretic Therapy |
2.8% |
| Acne |
2.4% |
| Oedema |
2.4% |
| Atrial Fibrillation |
2.0% |
| Chronic Obstructive Pulmonary Disease |
1.6% |
| Fallot's Tetralogy |
1.6% |
| Hyperlipidaemia |
1.6% |
| Prostate Cancer |
1.5% |
| Diabetes Mellitus |
1.4% |
| Oedema Peripheral |
1.4% |
| Transgender Hormonal Therapy |
1.4% |
| Blood Pressure Increased |
1.3% |
|
| Hyperkalaemia |
23.9% |
| Renal Failure Acute |
13.0% |
| Gynaecomastia |
9.3% |
| Vomiting |
6.5% |
| Weight Increased |
5.4% |
| Rash |
4.5% |
| Renal Failure |
3.9% |
| Blood Potassium Increased |
3.7% |
| Hypotension |
3.7% |
| Hyponatraemia |
3.4% |
| Renal Impairment |
3.4% |
| Hyperglycaemia |
2.5% |
| Nipple Pain |
2.5% |
| Syncope |
2.5% |
| Urticaria |
2.5% |
| Diarrhoea |
2.0% |
| Dyspnoea |
2.0% |
| Vision Blurred |
2.0% |
| Drug Ineffective |
1.7% |
| Hypokalaemia |
1.7% |
|
| Secondary |
| Product Used For Unknown Indication |
29.6% |
| Hypertension |
23.3% |
| Drug Use For Unknown Indication |
10.2% |
| Cardiac Failure |
8.1% |
| Atrial Fibrillation |
4.0% |
| Cardiac Failure Congestive |
3.1% |
| Type 2 Diabetes Mellitus |
2.9% |
| Chronic Obstructive Pulmonary Disease |
2.7% |
| Diabetes Mellitus |
1.9% |
| Cardiac Disorder |
1.8% |
| Cardiac Failure Chronic |
1.8% |
| Pain |
1.7% |
| Oedema |
1.5% |
| Ascites |
1.4% |
| Hypothyroidism |
1.3% |
| Muscle Spasms |
1.2% |
| Pneumonia |
1.0% |
| Coronary Artery Disease |
0.9% |
| Asthma |
0.9% |
| Diuretic Therapy |
0.9% |
|
| Renal Failure Acute |
21.3% |
| Hyperkalaemia |
14.4% |
| Renal Failure |
9.5% |
| Vomiting |
6.9% |
| Weight Increased |
6.9% |
| Syncope |
4.5% |
| Therapeutic Agent Toxicity |
4.4% |
| Hyponatraemia |
3.8% |
| Renal Impairment |
3.5% |
| Nausea |
2.9% |
| Hypotension |
2.7% |
| Mesothelioma |
2.7% |
| Weight Decreased |
2.5% |
| Toxic Epidermal Necrolysis |
2.4% |
| Death |
2.3% |
| Dehydration |
2.2% |
| Malaise |
2.1% |
| Allergic Myocarditis |
1.8% |
| Skin Ulcer |
1.7% |
| Cardiac Failure |
1.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
29.9% |
| Drug Use For Unknown Indication |
17.0% |
| Hypertension |
10.3% |
| Pulmonary Arterial Hypertension |
4.1% |
| Pain |
3.8% |
| Cardiac Failure |
3.6% |
| Diabetes Mellitus |
3.4% |
| Atrial Fibrillation |
3.3% |
| Prophylaxis |
2.8% |
| Rheumatoid Arthritis |
2.7% |
| Depression |
2.5% |
| Cardiac Disorder |
2.4% |
| Cardiac Failure Congestive |
2.3% |
| Pulmonary Hypertension |
2.0% |
| Type 2 Diabetes Mellitus |
1.9% |
| Hepatitis C |
1.8% |
| Chronic Obstructive Pulmonary Disease |
1.7% |
| Blood Cholesterol Increased |
1.6% |
| Gastrooesophageal Reflux Disease |
1.5% |
| Asthma |
1.4% |
|
| Vomiting |
14.2% |
| Weight Decreased |
8.4% |
| Weight Increased |
8.2% |
| Death |
7.8% |
| Renal Failure Acute |
5.1% |
| Nausea |
4.8% |
| Pneumonia |
4.7% |
| Urinary Tract Infection |
4.7% |
| Renal Failure |
4.6% |
| Pain |
4.6% |
| Thrombocytopenia |
3.8% |
| Dyspnoea |
3.8% |
| Oedema Peripheral |
3.5% |
| Renal Impairment |
3.5% |
| Syncope |
3.2% |
| Drug Ineffective |
3.2% |
| Pulmonary Embolism |
3.1% |
| Myocardial Infarction |
3.0% |
| Sepsis |
2.9% |
| Pyrexia |
2.9% |
|
| Interacting |
| Hypertension |
28.5% |
| Drug Use For Unknown Indication |
13.7% |
| Product Used For Unknown Indication |
9.7% |
| Pain |
7.3% |
| Cardiac Failure |
6.9% |
| Type 2 Diabetes Mellitus |
6.1% |
| Atrial Fibrillation |
4.7% |
| Hyperlipidaemia |
3.3% |
| Hepatitis C |
3.1% |
| Haemorrhage |
2.1% |
| Ischaemic Heart Disease Prophylaxis |
2.1% |
| Schizophrenia |
2.1% |
| Glaucoma |
1.9% |
| Oedema |
1.6% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.4% |
| Pulmonary Arterial Hypertension |
1.4% |
| Renal Failure Chronic |
1.2% |
| Diabetes Mellitus |
1.0% |
| Fallot's Tetralogy |
1.0% |
| Intervertebral Discitis |
1.0% |
|
| Renal Failure Acute |
29.1% |
| Drug Interaction |
12.8% |
| Vomiting |
11.6% |
| Hyperkalaemia |
10.5% |
| Renal Failure |
5.8% |
| Urine Potassium Increased |
3.5% |
| Dehydration |
2.3% |
| General Physical Health Deterioration |
2.3% |
| Hyperglycaemia |
2.3% |
| Hypotension |
2.3% |
| Pancytopenia |
2.3% |
| Renal Impairment |
2.3% |
| Shock |
2.3% |
| Skin Discolouration |
2.3% |
| Syncope |
2.3% |
| Acute Prerenal Failure |
1.2% |
| Bile Duct Stone |
1.2% |
| Blood Creatinine Increased |
1.2% |
| Blood Glucose Fluctuation |
1.2% |
| Cough |
1.2% |
|
